ANI Pharmaceuticals 2026 Watchlist: Gout Sales Force and Rare Disease
Culture Index
Score Breakdown
Relevance
9/25
Freshness
25/25
Authority
18/20
Brand Signal
6/15
Depth
2/15
5-Axis Cultural Radar
ANIP eyes 2026 pivot as Rare Disease targets 60% of sales, with Cortrophin growth, gout sales force expansion, and retina rebound shaping momentum.
